| Aug 16 |
GSK trades in the green for seventh straight session
|
| Aug 16 |
GSK to seek dismissal of Zantac lawsuit after favorable court ruling in Florida
|
| Aug 16 |
Florida Ruling Upholds GSK's Stance On Once Popular Heart Burn Drug Zantac Not Being Associated With Cancer Risk
|
| Aug 10 |
GSK plc (GSK): Why Are Hedge Funds Bullish on This Undervalued UK Stock Now?
|
| Aug 7 |
There May Be Reason For Hope In GSK's (LON:GSK) Disappointing Earnings
|
| Aug 6 |
Myriad Genetics Reports Strong Second Quarter 2024 Financial Results, including 15% Revenue Growth Year-Over-Year; Raises 2024 Financial Guidance and Long-Term Revenue Growth Target to 12%
|
| Aug 6 |
GSK wins latest Zantac lawsuit in Illinois
|
| Aug 6 |
GSK: Robust Financials, Strong Portfolio And Sector Rotation To Defensives Make It A Buy
|
| Aug 6 |
GSK announces victory in Zantac cancer claim lawsuit
|
| Aug 5 |
GSK Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
|
